Pharmafile Logo
Pharmafocus logo
Advanced Search

NICE

Showing 15 posts of 857 posts found.

nice_new_london_office_internal_3_web

NICE rejects mycosis fungoides-type cutaneous T-cell lymphoma therapy over data concerns

August 5, 2020
Research and Development, Sales and Marketing Ledaga, NICE, lymphoma

NICE has announced its rejection of Ledaga (chlormethine gel), a topical therapy for the treatment of mycosis fungoides-type cutaneous T-cell …

News
nice_reception

Bavencio+Inylta combo approved or Cancer Drugs Fund in advanced renal cell carcinoma

July 31, 2020
Medical Communications, Sales and Marketing Merck, NICE, Pfizer, pharma

NICE has revealed that a combination of Merck KGaA’s Bavencio (avelumab) and Pfizer’s Inlyta (axitinib) will be made available as …

News

NICE shoots down Kyowa Kirin’s Poteligeo for NHS treatment of mycosis fungoides or Sézary syndrome

July 30, 2020
Sales and Marketing Kyowa Kirin, NICE, pharma

NICE has issued draft guidance that has shot down Kyowa Kirin’s therapy Poteligeo (mogamulizumab) for use on the NHS in …

News

Gilteritinib becomes first NICE-approved oral therapy for relapsed or refractory acute myeloid leukaemia

July 16, 2020
Sales and Marketing Atellas, NICE, UK, acute myeloid leukaemia, gilteritinib

NICE has revealed its recommendation of Astellas’ gilteritinib for routine use as a monotherapy on the NHS in England and …

News

NICE recommends Takeda’s Adcetris for previously untreated systemic anaplastic large cell lymphoma

July 9, 2020
Sales and Marketing Adcentris, NICE, Takeda, UK

NICE has announced it has recommended Takeda’s Adcetris (brentuximab vedotin), in combination with cyclophosphamide, doxorubicin and prednisone (CHP), for use …

News
nhs_hispioiotror

NICE to recommend Roche cancer treatment

June 26, 2020
Medical Communications NHS, NICE

NICE are set to recommend Roche’s Rozlytrek (Entrectinib) cancer treatment which will be the second histology drug to be recommended …

News

NICE knocks back Novartis’ Mayzent in secondary progressive multiple sclerosis over data gaps

June 25, 2020
Sales and Marketing Mayzent, NHS, NICE, Novartis

Novartis’ Mayzent (siponimod) has been unsuccessful in securing a recommendation from NICE for use on the NHS for the treatment …

News

NICE greenlights Roche’s Rozlytrek for ROS1+ advanced non-small cell lung cancer

June 15, 2020
Sales and Marketing NICE, Roche, Rozlytrek, UK, lung cancer

Roche’s Rozlytrek (entrectinib) has secured recommendation for NHS use in England and Wales after NICE backed the drug in final …

News

NICE reverses previous stance to recommend Roche’s Tecentriq in extensive-stage small-cell lung cancer

May 27, 2020
Research and Development, Sales and Marketing NICE, Roche, lung cancer, tecentriq

NHS patients with treatment-naïve extensive-stage small-cell lung cancer (ES-SCLC) in England and Wales will soon have access to a new …

News

NICE gives thumbs-up to Roche’s Kadcyla in HER2+ breast cancer sub-population

May 7, 2020
Sales and Marketing Cancer, Kadcyla, NHS, NICE, Roche, UK, breast cancer

NICE has revealed that it has recommended the NHS use of Roche’s Kadcyla (trastuzumab emtansine) for HER2+ breast cancer in …

News
janssen_latest_logo_on_sign_closer

NICE backtracks to approve Janssen’s Stelara in ulcerative colitis

April 28, 2020
Manufacturing and Production, Research and Development Janssen, NICE, Stelara, ulcerative colitis

NICE has recommended Janssen’s Stelara (ustekinumab) for the treatment of moderately to severely active ulcerative colitis (UC), a move which …

News

Bayer’s Vitrakvi becomes first tumour-agnostic therapy approved by NICE for NHS patients with NTRK fusion+ cancer

April 21, 2020
Manufacturing and Production, Sales and Marketing Bayer, Cancer, NICE, UK, Vitrakvi, tumour agnostic

Bayer’s oral TRK inhibitor Vitrakvi (larotrectinib) has just been recommended by NICE in the treatment of advanced neurotrophic tyrosine receptor …

News
gill-leng-380_x_215-1

NICE promotes Professor Gillian Leng as its new Chief Executive

March 18, 2020
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing NHS, NICE, UK, pharma

NICE, the drug watchdog for the NHS in England and Wales, has announced that it has promoted Professor Gillian Leng …

News
merck-keytruda

Keytruda rejected for NHS use for bladder cancer, will be removed from the Cancer Drugs Fund

March 12, 2020
Sales and Marketing Cancer, Kidney cancer, MSD, NHS, NICE, blader cancer, keytruda, pharma

MSD’s blockbuster immunotherapy Keytruda (pembrolizumab) has been knocked back by NICE for use on the NHS as a treatment for …

News
teva_copy

Teva’s Ajovy becomes first drug of its kind available on NHS for prevention of chronic migraine

March 12, 2020
Sales and Marketing NICE, Teva, ajovy, migraine, pharma

NICE has announced the authorisation of Teva’s anti-CGRP drug Ajovy (fremanezumab) for the prevention of chronic migraine in adult patients …

News

Latest content

AbbVie invests €150m in new R&D facility in Germany

May 3, 2024

AstraZeneca shares positive interim results from phase 3 lymphoma trial

May 3, 2024

Merck shares data from phase 3 trial of Keytruda for gastric cancers

May 2, 2024

Verona Pharma to share phase 3 COPD trial data at ATS 2024

May 2, 2024

Beckman Coulter Life Sciences and Watchmaker Genomics enter collaboration

May 1, 2024